Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;33(1):101143.
doi: 10.1016/j.beha.2020.101143. Epub 2020 Jan 11.

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

Kitsada Wudhikarn  1 , Beatriz Wills  2 , Alexander M Lesokhin  3
Affiliations
Review

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

Kitsada Wudhikarn et al. Best Pract Res Clin Haematol. 2020 Mar.

Abstract

The recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-myeloma treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. Advances in biopharmaceutical engineering together with a robust interest in novel mAb-derivatives, including antibody drug conjugates and poly-specific antibodies are the next rapidly approaching treatment frontier in multiple myeloma. In this review, we comprehensively outline the currently available evidence and the future landscape of mAbs and mAb-derivative therapies in multiple myeloma.

Keywords: Antibody drug conjugate; Bispecific antibody; Monoclonal antibody; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest A.M.L. reports consultancy for Genmab, Bristol-Myers Squibb, and Takeda, honoraria from Genmab, Bristol-Myers Squibb, and Takeda, research grants from Genentech, Bristol-Myers Squibb, and Janssen, royalties from Serametrix. K.W. and B.W. declare no conflict of interests.

Figures

Figure 1:
Figure 1:
Current and investigational targets of mAbs in MM (modified from (66))
Figure 2:
Figure 2:
Concept of ADCs
Figure 3:
Figure 3:
Concept of bsAbs
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. - PubMed
    1. Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 2016;9(1):51. - PMC - PubMed
    1. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016;128(3):384–94. - PMC - PubMed
    1. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015;373(13):1207–19. - PubMed
    1. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387(10027):1551–60. - PubMed

Publication types

MeSH terms